+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
RNA Modifying Agents Market by Application (Diagnostics, Research Tools, Therapeutics), Agent Class (Erasers, Readers, Writers), Technology, End User, Modification Type, Target Disease - Global Forecast 2025-2030- Product Image
RNA Modifying Agents Market by Application (Diagnostics, Research Tools, Therapeutics), Agent Class (Erasers, Readers, Writers), Technology, End User, Modification Type, Target Disease - Global Forecast 2025-2030- Product Image
Sale

RNA Modifying Agents Market by Application (Diagnostics, Research Tools, Therapeutics), Agent Class (Erasers, Readers, Writers), Technology, End User, Modification Type, Target Disease - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 196 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6145522
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The science of RNA modifying agents has emerged as a cornerstone of modern molecular medicine, forging new pathways in diagnostics, research tools, and therapeutics. From the earliest characterization of enzymatic writers, erasers, and readers to the current surge in clinical trials targeting modification patterns, this dynamic field is redefining how we approach precision healthcare. Stakeholders across academia, biotechnology firms, and pharmaceutical companies are increasingly recognizing the transformative potential of tailored RNA modifications to influence gene expression, enhance diagnostic accuracy, and unlock novel treatment modalities.

This executive summary introduces the foundational concepts underlying RNA modifying agents, contextualizing their rise within the broader trajectory of genomic and transcriptomic innovation. It emphasizes how technological breakthroughs in mass spectrometry, microarray platforms, and high-throughput sequencing have converged to reveal complex modification landscapes. Furthermore, it underscores the strategic importance of these agents in tackling a spectrum of diseases, positioning them as versatile tools that bridge the gap between basic research and commercial therapeutic development.

Analyzing the Recent Transformative Shifts in RNA Modification Research That Are Reshaping Diagnostic Approaches and Therapeutic Innovations Globally

In recent years, the landscape of RNA modifying agents has undergone seismic shifts driven by convergent advances in chemistry, informatics, and clinical validation. Novel extraction chemistries and site-specific detection methods have supplanted traditional bulk assays, enabling researchers to map modification patterns at single-nucleotide resolution. Concurrently, artificial intelligence-powered analytical pipelines have increased throughput and predictive power, accelerating the translation of raw data into actionable insights.

Moreover, the therapeutic arena has been invigorated by landmark studies demonstrating the efficacy of targeted modification modulators in preclinical models. Strategic partnerships between biotech innovators and contract research organizations have streamlined the pathway from discovery to first-in-human trials, underscoring a shift toward collaborative value networks. These transformative shifts collectively signal a new era in which RNA modifying agents are no longer niche curiosities but foundational elements in the toolkit of modern precision medicine.

Assessing the Cumulative Impact of United States Tariffs Introduced in 2025 on the Supply Chain Dynamics and Cost Structures within the RNA Modifying Agents Market

The introduction of United States tariffs in 2025 has exerted a pronounced effect on the cost structures and logistical frameworks underpinning the RNA modifying agents market. Import duties on key reagents, consumables, and instrument components have introduced incremental expenses that reverberate across the supply chain. As a result, manufacturers and end users alike are recalibrating procurement strategies, exploring alternative sourcing channels, and renegotiating supplier agreements to contain margin erosions.

In response to these evolving dynamics, many organizations have accelerated initiatives to localize manufacturing capabilities, thereby reducing exposure to cross-border duty fluctuations. Strategic inventory management practices are being complemented by predictive analytics to anticipate cost spikes and optimize order cycles. While these adaptations have mitigated short-term financial shocks, the broader cumulative impact underscores the need for flexible procurement frameworks and collaborative industry coalitions to ensure sustained access to critical assay reagents and instrumentation.

Uncovering Critical Insights from Multifaceted Market Segmentation Across Applications Agent Classes Technologies End Users Modification Types and Target Diseases

The RNA modifying agents market can be deconstructed through a multifaceted segmentation lens that reveals nuanced growth corridors and competitive battlegrounds. When segmenting by application, it becomes clear that diagnostics and research tools serve as critical enablers, yet it is the therapeutics subset-spanning genetic disorders, infectious diseases, neurological disorders, and oncology-that commands escalating R&D focus. This therapeutic emphasis is bolstered by regulatory incentives and breakthrough designations, which have invigorated pipeline expansion.

Examining the agent class dimension highlights a balanced ecosystem comprising erasers, readers, and writers, each fulfilling distinct mechanistic roles in modulating transcripts. Meanwhile, technology segmentation underscores the complementary roles of mass spectrometry, microarray analysis, and sequencing platforms in decoding modification landscapes. In parallel, end users range from academic and research institutes to contract research organizations and pharmaceutical and biotech companies, reflecting a broad adoption profile across discovery and commercialization stages.

A deeper dive into modification type segmentation-encompassing M1A, M5C, M6A, and pseudouridine-reveals differential research intensity and therapeutic potential, with M6A emerging as a focal point for immune-modulatory strategies. Finally, target disease segmentation reiterates the pivotal relevance of genetic disorders, infectious diseases, neurological disorders, and oncology, each presenting unique biomarker and intervention opportunities that drive strategic investment priorities.

Evaluating Key Regional Dynamics across the Americas Europe Middle East Africa and Asia Pacific That Drive Adoption and Innovation in RNA Modifying Agents

Regional dynamics in the RNA modifying agents ecosystem reveal distinct opportunity structures shaped by local regulatory landscapes, research infrastructure, and investment climates. In the Americas, a robust network of academic centers and private biotech ventures fuels rapid adoption of cutting-edge modification assays and therapeutic candidates, supported by well-established translational funding mechanisms.

Across Europe, the Middle East & Africa region, harmonized regulatory frameworks and collaborative consortia have enabled large-scale clinical studies, while targeted government grants accelerate foundational research in RNA biology. Meanwhile, in the Asia-Pacific region, agile manufacturing capabilities, competitive pricing, and growing contract research capacity have positioned several countries as emerging hubs for reagent production and assay development. These regional insights illuminate the importance of aligning market entry strategies with localized regulatory policies, infrastructure capabilities, and funding landscapes.

Highlighting Strategic Moves Product Developments and Collaborations of Leading Companies Shaping the Future of the RNA Modifying Agents Industry

Leading stakeholders in the RNA modifying agents sphere are deploying a diverse array of strategic initiatives to secure competitive advantages. Biopharmaceutical companies are building proprietary libraries of modification modulators and forging collaborations with specialized technology providers to access novel detection platforms. Concurrently, pure-play biotech firms are focusing on platform expansion through in-licensing agreements and strategic minority investments that broaden their agent portfolios.

Meanwhile, contract research organizations are enhancing service offerings by integrating multi-omics and computational biology capabilities, thereby attracting larger discovery programs. Strategic partnerships between reagent manufacturers and sequencing technology leaders are catalyzing end-to-end solutions that streamline workflows from sample preparation through data interpretation. As the landscape grows more contested, the ability to deliver integrated, scalable, and fully validated offerings will distinguish market leaders from followers.

Providing Actionable Strategic Recommendations for Industry Leaders to Capitalize on Emerging Opportunities and Mitigate Risks in RNA Modification Frontiers

Industry leaders must adopt a proactive posture to harness the unfolding potential of RNA modifying agents. First, forging cross-sector partnerships can accelerate the co-development of next-generation detection platforms and therapeutic candidates. By aligning with specialized reagent suppliers, end users can co-innovate solutions tailored to critical research and clinical requirements.

Second, diversifying manufacturing footprints across low-tariff jurisdictions will mitigate supply chain risks and stabilize cost structures. Investing in regional production hubs and flexible contract manufacturing agreements ensures resilient access to high-quality reagents. Third, integrating advanced data analytics and machine learning approaches will enhance modification profiling accuracy and speed, enabling more precise biomarker discovery and patient stratification.

Finally, engaging early with regulatory authorities to define clear validation pathways and clinical end points will expedite product approvals and market entry. Together, these recommendations form a cohesive blueprint for stakeholders aiming to lead in this highly dynamic and rapidly advancing field.

Explaining the Comprehensive Research Methodology Employed for Analyzing Data Sources Expert Interviews and Market Validation Processes in RNA Modifying Agents Study

This market study synthesizes insights derived from a rigorous combination of primary and secondary research methodologies. Primary research entailed in-depth interviews with senior executives at biopharma companies, technology providers, and contract research organizations, alongside consultations with key opinion leaders in RNA biology and clinical development. These dialogues provided qualitative perspectives on market drivers, competitive strategies, and regulatory considerations.

Secondary research encompassed a comprehensive review of scientific literature, patent filings, clinical trial registries, and regulatory databases to validate and triangulate quantitative data. Proprietary analytical models were employed to assess technology adoption curves, cost-benefit analyses, and scenario planning. Data accuracy was ensured through cross-validation checks, while methodological limitations and assumptions were transparently documented.

Together, these research approaches deliver a robust and holistic view of the RNA modifying agents landscape, equipping stakeholders with the evidence-based insights needed to make strategic decisions in an evolving marketplace.

Drawing Conclusive Perspectives on the Evolution Market Drivers and Future Potential of RNA Modifying Agents in the Era of Precision Medicine and Therapeutic Innovation

The evolution of RNA modifying agents has reached an inflection point, marked by accelerated technological innovation, expanding therapeutic pipelines, and shifting regulatory landscapes. The convergence of high-resolution detection methods with targeted modification modulators heralds a new era in precision medicine, offering unprecedented avenues for diagnosis, prognosis, and intervention across a spectrum of diseases.

While challenges such as supply chain vulnerabilities and tariff-induced cost pressures persist, adaptive strategies and collaborative ecosystems are emerging to surmount these obstacles. Regional market nuances underscore the need for tailored go-to-market approaches, and a keen focus on stakeholder partnerships will be instrumental in driving sustainable growth. Ultimately, the insights presented herein serve as a strategic compass for industry participants seeking to capitalize on the immense promise of RNA modifying agents and chart the course for future innovations.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Application
    • Diagnostics
    • Research Tools
    • Therapeutics
      • Genetic Disorders
      • Infectious Diseases
      • Neurological Disorders
      • Oncology
  • Agent Class
    • Erasers
    • Readers
    • Writers
  • Technology
    • Mass Spectrometry
    • Microarray
    • Sequencing
  • End User
    • Academic And Research Institutes
    • Contract Research Organizations
    • Pharmaceutical And Biotech Companies
  • Modification Type
    • M1A
    • M5C
    • M6A
    • Pseudouridine
  • Target Disease
    • Genetic Disorders
    • Infectious Diseases
    • Neurological Disorders
    • Oncology
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies Inc.
  • QIAGEN N.V.
  • Bio-Techne Corporation
  • New England Biolabs, Inc.
  • PerkinElmer, Inc.
  • Promega Corporation
  • Takara Bio Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emerging epitranscriptomic biomarkers enabling personalized RNA modification therapies at scale
5.2. Integration of mRNA delivery platforms with novel lipid nanoparticle formulations for improved cellular uptake
5.3. Development of site-specific pseudouridine synthetic pathways to enhance mRNA stability and translational efficiency
5.4. Collaboration between biotech firms and academic institutions to accelerate RNA modifying enzyme discovery
5.5. Regulatory harmonization efforts accelerating approval pathways for RNA modification-based therapeutics
5.6. Expansion of automated high throughput screening platforms for discovering novel RNA modification targets
5.7. Investment surge in RNA epitranscriptome editing startups driven by oncology and rare disease applications
5.8. Advances in computational design of guide RNAs improving specificity and reducing off-target RNA modifications
5.9. Implementation of artificial intelligence models for predicting outcomes of novel RNA modification chemistries
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. RNA Modifying Agents Market, by Application
8.1. Introduction
8.2. Diagnostics
8.3. Research Tools
8.4. Therapeutics
8.4.1. Genetic Disorders
8.4.2. Infectious Diseases
8.4.3. Neurological Disorders
8.4.4. Oncology
9. RNA Modifying Agents Market, by Agent Class
9.1. Introduction
9.2. Erasers
9.3. Readers
9.4. Writers
10. RNA Modifying Agents Market, by Technology
10.1. Introduction
10.2. Mass Spectrometry
10.3. Microarray
10.4. Sequencing
11. RNA Modifying Agents Market, by End User
11.1. Introduction
11.2. Academic And Research Institutes
11.3. Contract Research Organizations
11.4. Pharmaceutical And Biotech Companies
12. RNA Modifying Agents Market, by Modification Type
12.1. Introduction
12.2. M1A
12.3. M5C
12.4. M6A
12.5. Pseudouridine
13. RNA Modifying Agents Market, by Target Disease
13.1. Introduction
13.2. Genetic Disorders
13.3. Infectious Diseases
13.4. Neurological Disorders
13.5. Oncology
14. Americas RNA Modifying Agents Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa RNA Modifying Agents Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific RNA Modifying Agents Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Thermo Fisher Scientific Inc.
17.3.2. Merck KGaA
17.3.3. Danaher Corporation
17.3.4. Agilent Technologies Inc.
17.3.5. QIAGEN N.V.
17.3.6. Bio-Techne Corporation
17.3.7. New England Biolabs, Inc.
17.3.8. PerkinElmer, Inc.
17.3.9. Promega Corporation
17.3.10. Takara Bio Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. RNA MODIFYING AGENTS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS RNA MODIFYING AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS RNA MODIFYING AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES RNA MODIFYING AGENTS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES RNA MODIFYING AGENTS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA RNA MODIFYING AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA RNA MODIFYING AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC RNA MODIFYING AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC RNA MODIFYING AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. RNA MODIFYING AGENTS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. RNA MODIFYING AGENTS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. RNA MODIFYING AGENTS MARKET: RESEARCHAI
FIGURE 28. RNA MODIFYING AGENTS MARKET: RESEARCHSTATISTICS
FIGURE 29. RNA MODIFYING AGENTS MARKET: RESEARCHCONTACTS
FIGURE 30. RNA MODIFYING AGENTS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. RNA MODIFYING AGENTS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY RESEARCH TOOLS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY RESEARCH TOOLS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY ERASERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY ERASERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY READERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY READERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY WRITERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY WRITERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY MICROARRAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY M1A, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY M1A, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY M5C, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY M5C, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY M6A, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY M6A, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY PSEUDOURIDINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY PSEUDOURIDINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL RNA MODIFYING AGENTS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS RNA MODIFYING AGENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS RNA MODIFYING AGENTS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES RNA MODIFYING AGENTS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES RNA MODIFYING AGENTS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 103. CANADA RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 104. CANADA RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 105. CANADA RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 106. CANADA RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 107. CANADA RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2018-2024 (USD MILLION)
TABLE 108. CANADA RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2025-2030 (USD MILLION)
TABLE 109. CANADA RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 110. CANADA RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 111. CANADA RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 112. CANADA RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 113. CANADA RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2018-2024 (USD MILLION)
TABLE 114. CANADA RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2025-2030 (USD MILLION)
TABLE 115. CANADA RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2018-2024 (USD MILLION)
TABLE 116. CANADA RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2025-2030 (USD MILLION)
TABLE 117. MEXICO RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 118. MEXICO RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 119. MEXICO RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 120. MEXICO RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 121. MEXICO RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2018-2024 (USD MILLION)
TABLE 122. MEXICO RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2025-2030 (USD MILLION)
TABLE 123. MEXICO RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 124. MEXICO RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 125. MEXICO RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. MEXICO RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. MEXICO RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2018-2024 (USD MILLION)
TABLE 128. MEXICO RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2025-2030 (USD MILLION)
TABLE 129. MEXICO RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2018-2024 (USD MILLION)
TABLE 130. MEXICO RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2025-2030 (USD MILLION)
TABLE 145. ARGENTINA RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 146. ARGENTINA RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2025-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA RNA MODIFYING AGENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA RNA MODIFYING AGENTS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 176. UNITED KINGDOM RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 178. UNITED KINGDOM RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2018-2024 (USD MILLION)
TABLE 180. UNITED KINGDOM RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2025-2030 (USD MILLION)
TABLE 189. GERMANY RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 190. GERMANY RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 191. GERMANY RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 192. GERMANY RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 193. GERMANY RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2018-2024 (USD MILLION)
TABLE 194. GERMANY RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2025-2030 (USD MILLION)
TABLE 195. GERMANY RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 196. GERMANY RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 197. GERMANY RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. GERMANY RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. GERMANY RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2018-2024 (USD MILLION)
TABLE 200. GERMANY RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2025-2030 (USD MILLION)
TABLE 201. GERMANY RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2018-2024 (USD MILLION)
TABLE 202. GERMANY RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2025-2030 (USD MILLION)
TABLE 203. FRANCE RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 204. FRANCE RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 205. FRANCE RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 206. FRANCE RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 207. FRANCE RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2018-2024 (USD MILLION)
TABLE 208. FRANCE RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2025-2030 (USD MILLION)
TABLE 209. FRANCE RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 210. FRANCE RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 211. FRANCE RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 212. FRANCE RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 213. FRANCE RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2018-2024 (USD MILLION)
TABLE 214. FRANCE RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2025-2030 (USD MILLION)
TABLE 215. FRANCE RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2018-2024 (USD MILLION)
TABLE 216. FRANCE RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2025-2030 (USD MILLION)
TABLE 217. RUSSIA RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 218. RUSSIA RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 219. RUSSIA RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 220. RUSSIA RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 221. RUSSIA RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2018-2024 (USD MILLION)
TABLE 222. RUSSIA RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2025-2030 (USD MILLION)
TABLE 223. RUSSIA RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 224. RUSSIA RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 225. RUSSIA RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 226. RUSSIA RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 227. RUSSIA RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2018-2024 (USD MILLION)
TABLE 228. RUSSIA RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2025-2030 (USD MILLION)
TABLE 229. RUSSIA RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2018-2024 (USD MILLION)
TABLE 230. RUSSIA RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2025-2030 (USD MILLION)
TABLE 231. ITALY RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 232. ITALY RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 233. ITALY RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 234. ITALY RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 235. ITALY RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2018-2024 (USD MILLION)
TABLE 236. ITALY RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2025-2030 (USD MILLION)
TABLE 237. ITALY RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 238. ITALY RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 239. ITALY RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. ITALY RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 241. ITALY RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2018-2024 (USD MILLION)
TABLE 242. ITALY RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2025-2030 (USD MILLION)
TABLE 243. ITALY RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2018-2024 (USD MILLION)
TABLE 244. ITALY RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2025-2030 (USD MILLION)
TABLE 245. SPAIN RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 246. SPAIN RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 247. SPAIN RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 248. SPAIN RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 249. SPAIN RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2018-2024 (USD MILLION)
TABLE 250. SPAIN RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2025-2030 (USD MILLION)
TABLE 251. SPAIN RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 252. SPAIN RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 253. SPAIN RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. SPAIN RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. SPAIN RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2018-2024 (USD MILLION)
TABLE 256. SPAIN RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2025-2030 (USD MILLION)
TABLE 257. SPAIN RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2018-2024 (USD MILLION)
TABLE 258. SPAIN RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2025-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 260. UNITED ARAB EMIRATES RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 261. UNITED ARAB EMIRATES RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 262. UNITED ARAB EMIRATES RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 263. UNITED ARAB EMIRATES RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2018-2024 (USD MILLION)
TABLE 264. UNITED ARAB EMIRATES RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2025-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 269. UNITED ARAB EMIRATES RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2018-2024 (USD MILLION)
TABLE 270. UNITED ARAB EMIRATES RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2025-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2018-2024 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2025-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 274. SAUDI ARABIA RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 276. SAUDI ARABIA RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2018-2024 (USD MILLION)
TABLE 278. SAUDI ARABIA RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2025-2030 (USD MILLION)
TABLE 279. SAUDI ARABIA RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 280. SAUDI ARABIA RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 281. SAUDI ARABIA RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 282. SAUDI ARABIA RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 283. SAUDI ARABIA RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2018-2024 (USD MILLION)
TABLE 284. SAUDI ARABIA RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2025-2030 (USD MILLION)
TABLE 285. SAUDI ARABIA RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2018-2024 (USD MILLION)
TABLE 286. SAUDI ARABIA RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2025-2030 (USD MILLION)
TABLE 287. SOUTH AFRICA RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 288. SOUTH AFRICA RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 289. SOUTH AFRICA RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 290. SOUTH AFRICA RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 291. SOUTH AFRICA RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2018-2024 (USD MILLION)
TABLE 292. SOUTH AFRICA RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2025-2030 (USD MILLION)
TABLE 293. SOUTH AFRICA RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 294. SOUTH AFRICA RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 295. SOUTH AFRICA RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 296. SOUTH AFRICA RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 297. SOUTH AFRICA RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2018-2024 (USD MILLION)
TABLE 298. SOUTH AFRICA RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2025-2030 (USD MILLION)
TABLE 299. SOUTH AFRICA RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2018-2024 (USD MILLION)
TABLE 300. SOUTH AFRICA RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2025-2030 (USD MILLION)
TABLE 301. DENMARK RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 302. DENMARK RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 303. DENMARK RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 304. DENMARK RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 305. DENMARK RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2018-2024 (USD MILLION)
TABLE 306. DENMARK RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2025-2030 (USD MILLION)
TABLE 307. DENMARK RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 308. DENMARK RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 309. DENMARK RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 310. DENMARK RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 311. DENMARK RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2018-2024 (USD MILLION)
TABLE 312. DENMARK RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2025-2030 (USD MILLION)
TABLE 313. DENMARK RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2018-2024 (USD MILLION)
TABLE 314. DENMARK RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2025-2030 (USD MILLION)
TABLE 315. NETHERLANDS RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 316. NETHERLANDS RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 317. NETHERLANDS RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 318. NETHERLANDS RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 319. NETHERLANDS RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2018-2024 (USD MILLION)
TABLE 320. NETHERLANDS RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2025-2030 (USD MILLION)
TABLE 321. NETHERLANDS RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 322. NETHERLANDS RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 323. NETHERLANDS RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 324. NETHERLANDS RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 325. NETHERLANDS RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2018-2024 (USD MILLION)
TABLE 326. NETHERLANDS RNA MODIFYING AGENTS MARKET SIZE, BY MODIFICATION TYPE, 2025-2030 (USD MILLION)
TABLE 327. NETHERLANDS RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2018-2024 (USD MILLION)
TABLE 328. NETHERLANDS RNA MODIFYING AGENTS MARKET SIZE, BY TARGET DISEASE, 2025-2030 (USD MILLION)
TABLE 329. QATAR RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 330. QATAR RNA MODIFYING AGENTS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 331. QATAR RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 332. QATAR RNA MODIFYING AGENTS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 333. QATAR RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2018-2024 (USD MILLION)
TABLE 334. QATAR RNA MODIFYING AGENTS MARKET SIZE, BY AGENT CLASS, 2025-2030 (USD MILLION)
TABLE 335. QATAR RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 336. QATAR RNA MODIFYING AGENTS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 337. QATAR RNA MODIFYING AGENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 338. QATA

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this RNA Modifying Agents market report include:
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies Inc.
  • QIAGEN N.V.
  • Bio-Techne Corporation
  • New England Biolabs, Inc.
  • PerkinElmer, Inc.
  • Promega Corporation
  • Takara Bio Inc.

Related Reports

Huntington's Disease Treatment Market by Treatment Type (Disease Modifying Therapies, Emerging Therapies, Symptomatic Therapies), Therapeutic Class (Cell Based Agents, Gene Silencing Agents, Neuroprotective Agents), Delivery Mode, End User - Global Forecast 2025-2030 - Product Image

Huntington's Disease Treatment Market by Treatment Type (Disease Modifying Therapies, Emerging Therapies, Symptomatic Therapies), Therapeutic Class (Cell Based Agents, Gene Silencing Agents, Neuroprotective Agents), Delivery Mode, End User - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
Enzymatic Targets for Drug Discovery Against Alzheimer's Disease - Product Image

Enzymatic Targets for Drug Discovery Against Alzheimer's Disease

  • Book
DNA Modifying Agents Market by Technology (Crispr Cas Systems, Meganucleases, Talens), Application (Agriculture And Animal Biotechnology, Industrial Biotechnology, Research And Diagnostics), End User - Global Forecast 2025-2030 - Product Image

DNA Modifying Agents Market by Technology (Crispr Cas Systems, Meganucleases, Talens), Application (Agriculture And Animal Biotechnology, Industrial Biotechnology, Research And Diagnostics), End User - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Epigenetics Drugs and Diagnostic Technologies Market Report 2025 - Product Image

Epigenetics Drugs and Diagnostic Technologies Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Huntington's Disease Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035 - Product Image

Huntington's Disease Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035

  • Report
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.